Marrow aplasia congenital red series: Diamond Blackfan Anemia. About a case
Keywords:
marrow red cell aplasia, Diamond-Blackfan anemia, severe anemia, bone marrow aplasia congenital.Abstract
Pure red cell aplasia medullary is a disorder characterized by anemia with almost complete absence of red cell precursors in the bone marrow, with leukocyte count and platelets. The Diamond-Blackfan anemia is a failure syndrome characterized by bone marrow anemia, reticulocytopenia and decreased erythroid precursors in the bone marrow. the case of an infant under 2 months of age presented no family or perinatal history major, whose mother progressive skin pallor evidence mucosa associated with hyporexia; go to health center where they perform paraclinical reporting hemoglobin 1.7 g / dL. peripheral blood smear where erythroid frankly affected with normal megakaryocytic granulocytic count shown is made; It biopsied and bone marrow aspirate concluding marrow red cell aplasia; possible anemia Diamond-Blackfan in light of other clinical findings arises. It stays with glucocorticoid treatment, however insufficient response, begins erythropoietin dose progressively increasing, despite it, warrants blood transfusions on a regular basis; compatibility studies performed with first-degree resulting positive, currently a candidate for allogeneic bone marrow transplantation. It is concluded that despite being a rare syndrome should be suspected in severe anemia where there is acute blood loss, ruling out other etiologies; also timely initiation of treatment is critical to the survival of these patients.Downloads
References
Paul F. Review Pure red cell aplasia. British Journal of Haematology. 2008; 111: 1010-1022.
González P. Aplasia pura de serie roja. Rev Hematol. 2006; 7(3): 127-13.
Trautmann K. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and Diamond – Blackfa Anemia. Thromb Haemost. 2012; 108(2): 397-8.
Toki T, Ito E. Molecular mechanisms underlying the pathology of Diamond-Blackfan anemia. Rinsho Ketsueki – The Japanese Journal of Clinical Hematology. 2015; 56(7): 867-76.
Willig TN, et al. Diamond-Blackfan anemia. Current Opinion in Hematology. 2000; 7:85-94.
Smetanina N, Mersiyanova I, et al. Clinical and genomic heterogeneity of Diamond Blackfan anemia in the Russian Federation. Pediatr Blood Cancer. 2015; 62(9): 1597-600.
Gazda HT, et al. Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-rRNA processing defect in Diamond-Blackfan anemia. Human Mutation. 2012; 33:1037–1044.
Wang R, Yoshida K, Toki T, Shiraishi Y, Chiba K, et al. Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia. Br J Haematol. 2015; 168(6): 854-64.
Campagnoli M, Garelli E, Quarello P, et al. Molecular basis of Diamond-Blackfan anemia: New findings from the Italian registry and a review of the literature. Haematologica. 2004; 89:480–489.
Lipton J, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: An update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006; 46: 558–564.
Roggero S, Quarello P, et al. Severe iron overload in Blackfan-Diamond anemia: A case-control study. Am J Hematol. 2009; 84:729–732.
Rastislav H, von Lindern M. Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia. British Journal of Haematology. 2012; 159:514–527.
Domínguez-Rodríguez K, De la Vega L, Rodríguez-Alcocer A. Aplasia pura de serie roja en niña de la etnia mexicana rarámuri. Rev Hematol Mex. 2016; 17(3):225-228.
How to Cite
Issue
Section
License
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material
- para cualquier propósito, incluso comercialmente.
Bajo los siguientes términos:
-
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.